Russian authorities have recently given regulatory approval to its second coronavirus vaccine dubbed EpiVacCorona after early-stage studies, revealed Russia’s President Vladimir Putin.
The peptide-based vaccine was developed by the Vector State Research Centre of Virology and Biotechnology, in Siberia and tested among 100 volunteers in the placebo-controlled human trials which lasted for more than two months. Volunteers aged between 18 and 60 years were included in the study.
Unlike the first Russian vaccine “Sputnik V”, which is a vector vaccine, the new vaccine was created on the basis of synthetic platforms. EpiVacCorona is a peptide vaccine, that consists of artificially synthesized short fragments of viral peptides as antigens, which the immune system learns and subsequently recognises and neutralises the virus.
The scientists have yet to publish the results of the study. Commenting on the study, the scientists said that the vaccine produced enough antibodies to protect the person who had it from the virus and that the immunity it creates could last for up to six months.
An advanced study involving approximately 40,000 volunteers would start by the end of 2020 to establish safety and effectiveness of the vaccine, said Deputy Prime Minister Tatyana Golikova.
Russia’s first vaccine, Sputnik V, was developed by the Moscow-based Gamaleya Institute and approved by the government on August11, after early trials among 76 volunteers were completed.
Putin said that a third Russian vaccine against COVID-19, developed by the Chumakov Centre, would also be registered in the near future, Sputnik news agency reported.